LongBio Pharma (Suzhou) Co., Ltd. reported that all five resolutions tabled at its 30 June 2026 annual general meeting were approved by poll, confirming broad shareholder support for the company’s 2025 financials, dividend proposal, auditor re-appointment, and refreshed capital mandates.

Shareholder turnout reached 59.32%, with 44.01 million shares voting out of 74.19 million issued.

1. 2025 Accountant’s Report & Profit Distribution • Both items secured unanimous backing, receiving 100.00% of the votes cast.

2. Auditor Re-appointment • Ernst & Young was re-appointed for the 2026 financial year with 100.00% support; the board is authorised to fix remuneration.

3. General Mandates • Issuance mandate: approved by 98.52% of votes, allowing the board to issue new shares up to the prescribed limit. • H-share repurchase mandate: passed with 100.00% approval, permitting market buybacks within regulatory caps.

No shareholders were required to abstain, and none voted against any ordinary resolutions. Tricor Investor Services and two shareholder representatives acted as scrutineers. All directors attended the meeting, ensuring compliance with the Company Law and the Articles of Association.